Vaxneuvance

(Pneumococcal 15-valent Conjugate Vaccine) Merck Sharp & Dohme Corp.

• Vaxneuvance is a 15-valent PCV containing 13 serotypes in licensed PCV13 and 2 additional serotypes (22F, 33F) which significantly contribute to pneumococcal disease burden.²

• Vaxneuvance met noninferiority criteria compared to PCV13 for the 13 shared serotypes (using a 2-fold non-inferiority margin for the ratio of OPA geometric mean titers [GMTs] [V114/PCV13] at Day 30) and met superiority for the 2 unique serotypes.²

• Vaxneuvance met superiority criteria compared to PCV13 for serotype 3 (based on a super-superiority margin of 1.2 for the ratio of the OPA GMTs [V114/PCV13] and a superiority margin of 0 for the difference in proportions of participants with ≥4-fold rise).²

Reference:

2. Heather L. Platt, et al. Vaccine Volume 40, Issue 1, 3 January 2022, Pages 162-172.